Hollis-Eden Pharmaceuticals files $75 million shelf

By Jennifer Chiou

New York, June 16 - Hollis-Eden Pharmaceuticals, Inc. registered to sell up to $75 million of securities in an S-3 filing with the Securities and Exchange Commission.

Covered by the shelf are common stock and warrants.

Proceeds will go toward general corporate purposes.

San Diego-based Hollis-Eden develops small-molecule compounds that are metabolic conversion products or synthetic analogs of adrenal steroid hormones.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.